Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

Lancet. 2004 Aug 21-27;364(9435):685-96.

PMID:
15325833
3.

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.

PMID:
17910521
4.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
6.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
7.

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Bybee KA, Lee JH, O'Keefe JH.

Curr Med Res Opin. 2008 Apr;24(4):1217-29. doi: 10.1185/030079908X292001 . Epub 2008 Mar 20. Review.

PMID:
18358084
8.
10.

Interpretation of the evidence for the efficacy and safety of statin therapy.

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R.

Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Review.

PMID:
27616593
11.

Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.

Riche DM, McClendon KS.

Am J Health Syst Pharm. 2007 Aug 1;64(15):1603-10. Review.

PMID:
17646562
12.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
13.
15.

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS.

JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985. Review.

PMID:
27673306
16.

Expanding roles for atorvastatin.

Singh V, Deedwania P.

Drugs Today (Barc). 2008 Jun;44(6):455-71. doi: 10.1358/dot.2008.44.6.1217468. Review.

PMID:
18596999
17.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004816.

18.

[Statins and unstable angina: MIRACL].

Puel J.

Ann Endocrinol (Paris). 2001 Feb;62(1 Pt 2):145-8. Review. French.

PMID:
11240417
19.

Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.

Novela C, Hennekens CH.

J Cardiovasc Pharmacol Ther. 2004 Mar;9(1):61-3. Review.

PMID:
15094970
20.

Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients.

Ye YC, Zhao XL, Zhang SY.

Chin Med J (Engl). 2015 Jan 20;128(2):259-66. doi: 10.4103/0366-6999.149226. Review.

Supplemental Content

Support Center